|This user is busy in real life and may not respond swiftly to queries.|
Welcome To My User Page
My name is Cliff Knickerbocker. I spend much of my limited time here creating and editing oncology-related articles, with particular emphasis on the many histological and molecular variants of lung cancer known as the "non-small cell lung carcinomas". I also enjoy doing peer reviews, am active with the Wikipedia Guild of Copy Editors, the Typo Team, and as a New Pages, Recent Changes, and Vandalism Patroller. I'm also a member of, and participate in, a number of Wikipedia Task Forces and other groups - for details, see the links and icons on my "Babel Tower", located on the right of this page.
If you'd like to collaborate on a specific Wikipedia article, or work together to develop and submit a manuscript for publication in a peer-reviewed academic journal, please leave me a note here. Thanks for stopping by!
My personal idiosyncrasies and breadth of interests have motivated me to pursue many and varied challenges over my professional lifetime. Over the past 40 years, I've worked as a mining engineer (1973-1985), a research virologist (1985-1986), a forensic chemist (1986-1989), a construction project manager building large draglines (1989-1993), a private investigator (1993-2012), a radiology patient care technician (2001-2003), an epidemiology researcher, lecturer, and research Fellow at a University (2002-2006), a medical researcher specializing in lung cancer (1997-2012), and a forensic and medical expert and consultant for various law firms (1993-2012).
Current Strategic Plan
I have recently relocated to St. Joseph, Missouri, and have been consulting with a number of area medical and business professionals regarding the scope and merit of my cancer research agenda. These meetings have been quite productive, and there is consensus that my approach is one with great potential (see discussion below).
I am in the beginning stages of identifying a team of individuals and investors to help me put together a "for-profit" cancer research entity that will specialize in the identification of effective treatments for less common forms of cancer for which there are (as yet) no generally accepted specific therapeutic regimens. The major target markets for our intellectual property will be pharmaceutical and biotechnology companies, hospitals, epidemiologists, tumor registries, academic researchers, and other specialized firms.
Current Research Projects and Agenda
- Variant Lung Tumor Database (VLTD)
- I've begun building a large database of demographic, clinical, pathological, immunohistochemical, molecular, and treatment response variables from individual patients with different histological subtypes and variants of NSCLC. To date, no randomized controlled clinical trials have been done that included stratification based on individual histological subtypes of NSCLC, only the major histological types (i.e. squamous cell carcinoma and adenocarcinoma, with the latter often containing other variants and being called "non-squamous" carcinoma). There are, however, many hundreds of case series and reports in the literature and in institutional databases that contain epidemiological, clinicopathological, and multimodal treatment data on subtypes, unusual variants, and combined histological forms of lung cancer in tens of thousands of patients that represent a "treasure trove" of information. If this data is properly mined, it could be used to generate compelling and robust statistical data to rationally guide current "off-label" treatment options and future trial designs that will produce more effective and less toxic treatments than the current paradigm that represents the status quo.
- Founding a New Lung Cancer Research Institute
- I have long maintained that multivariate statistical analyses using dynamic pooled data is the best tool we currently have for developing rational, evidence-based treatment paradigms for many of the less common variants of lung cancer. The VLTD I am building is intended to be used meta-analytically to identify and "pre-validate" novel and potentially effective treatment protocols for unusual lung cancer variants. Mining of databases such as the VLTD can produce compelling statistical data that strongly suggest that certain treatment regimens may be particularly efficacious when used for a given variant, as opposed to just choosing one of the generic "standard" therapies. Conversely - and perhaps just as importantly in some cases - the generated data may also suggest that various drugs or treatment regimens could be especially dangerous or toxic to the patient (see the giant cell carcinoma discussion below).
- During the past five years I have developed several theories about certain treatment regimens for different lung cancer variants that are backed by highly provocative and robust statistical data. I believe that the pharmaceutical industry will find these theories and data interesting, and potentially very lucrative. Therefore, once I am currently trying to obtain a research and teaching position with an academic institution that will be willing to seek funding from pharmaceutical companies, and other entities and individuals, to support further w
ork on these ideas. I am so confident of the merit of my approach, and the robustness of the data I havew developed, that I am prepred to invest substantial sums of personal capital into founding a new "Lung Cancer Research Institute" that I hope will benefit not only myself, but my new colleagues, employers, partners, and benefactors.
- Rare Lung Cancer Variant Manuscripts: I have begun several manuscripts using results from my analyses that are intended for publication. As an example, one of these will be a highly compelling and comprehensive meta-analysis and clinicopathological review of an extremely aggressive histological variant of NSCLC known as giant cell carcinoma of the lung (GCCL). GCCL belongs to the sarcomatoid carcinoma histological "class" of lung cancers. It resembles an anaplastic pulmonary sarcoma microscopically, and kills approximately 90% of its victims, often within just a few weeks or months. My research strongly suggests the following conclusions with regard to primary pulmonary giant cell carcinomas:
- 1. GCCL occurs statistically significantly more commonly in female non-smokers than it does in male non-smokers. This particular gender-smoking interaction is uncommon among lung cancer variants, suggesting that relatively unique mechanisms of pulmonary carcinogenesis are at play in these lesions;
- 2. GCCL is particularly likely to result in a primary tumor that is severely necrotic - and like squamous cell lung carcinoma - often produces a tumor that cavitates. Interestingly, however, while squamous cell carcinoma more commonly occurs as a central mass lesion in the lung, giant call carcinoma is much more likely to manifest itself as a large, peripherally located mass;
- 3. Given #2 above, patients with giant cell carcinomas may well be at greatly increased risk for severe or fatal hemoptysis if treated with Avastin (bevacizumab) or other angiogenesis inhibitors, as compared to other variants of NSCLC. This finding may be of particular importance, as this drug is rapidly becoming one of the most widely used agents in lung cancer. As it has been approved for (all) non-squamous NSCLC's, it could theoretically be chosen as part of a regimen to treat GCCL's, which could result in fatal consequences for the patient;
- 4. Patients with GCCL also appear particularly likely to eventually develop a primary tumor containing only a rim of viable, highly proliferating tumor cells at the perimeter of the tumor. My research also suggests that large cell lung carcinoma with rhabdoid phenotype, another usually highly lethal variant of NSCLC, also has an increased tendency to exhibit this particular pathophysiological behavior. These facts should be considered, I think, when a clinician makes the decision as to whether or not to use anti-angiogenesis agents in treatment.
- 5. GCCL may also be particularly responsive to treatment with certain agents (that I will keep secret for now), some of which are well-known drugs long used in the chemotherapy of lung cancer, and a few of which are lesser known "atypical" agents;
- 6. The unique development and particular aggressiveness of GCCL may be due in large part to a specific molecular oncogenetic driver mutation and/or pathway, and for which targeted drugs are currently available, but are not to my knowledge being tested for this purpose - the details on all this I will keep "secret" for now;
- 7. Several other general clinicopathological properties of GCCL will be "confirmed" by my data, and discussed comprehensively, in my forthcoming manuscript, which will reflect analyses using a much larger sample size than others have used in previous published metanalyses and case series on this particular entity.
- This particular manuscript will be completed and submitted as soon as I obtain a new position, but I'm posting some of the details here and now so that, in case anyone tries to "scoop" me, or plagiarize me (see below), I can at least offer some proof that I was the first to "discover" this material and "publish" it.
- The HOHMS Paradigm: Some years ago, when I worked as a Walton Distinguished Fellow at the University of Arkansas under my research mentor, Dr. Michael E. Young, I coined the term "Higher-Order Histomolecular Stratification" (with the acronym HOHMS). The HOHMS paradigm hypothesized that a much greater level of stratification of lung cancer patients, based on certain combinations of histological and molecular characteristics of particular tumor variants, would be mandatory before we could make "quantum leaps" in improving survival and quality of life (QOL) measures in the vast majority of lung cancer patients.
- If we could rationally expand the number of lung cancer patient strata in clinical trials so as to to get much more homogeneous groups of not just patients, but tumors (i.e. with more similar oncogenetic and metabolic pathways and drivers), then we should better be able to identify specific treatment regimens with improved efficacy and decreased toxicity in at least some of the many different lung cancer variants. Unfortunately, the cost of greatly increased stratification is that the groups we will be studying will get much smaller, which reduces the statistical power of the analyses, and makes it more difficult to show true differences and how big the differences are.
- Importantly, recent advances in lung cancer treatment have strongly suggested that differences can be relatively very large (several or many months), at least compared to those seen in the past (a few weeks to a few months). The larger these differences, the more confidence (generally speaking) we can have in them, so stratum size is less important than it would otherwise be.
- As discussed above, my VTTD will be used to try to develop, and pre-validate for further research, novel treatment regimens with metanalytical, post hoc statistical evidence. It can also be used to discover new epidemiological associations (see above), and even to infer possible mechanistic explanations or drivers for some of the cancerous phenotypes. At the same time, I will be using it to create and/or expand evidence-based frameworks for new "higher-order" lung cancer variant classification systems (see below).
- Lung Cancer Classification and Nomenclature Project
- The current rules for classifying lung cancer variants under the most widely used World Health Organization system, published in 2004 ("WHO-2004"), while extremely useful and a great improvement over previous classifications, remains to some extent fairly ambiguous, arbitrary, and incomplete.
- In addition, much of the most basic nomenclature used in identifying the different "groupings" of tumors and variants is unstandardized and inconsistent. I am currently working on a systematic framework for both these highly interrelated topics (incorporating the HOHMS paradigm) that I suggest represents a significant improvement, supplement, and complement over, and to, the WHO-2004 system that nonetheless retains the vast majority of this works essential concepts and organization.
Other Medical Research Experience
I also have research expertise with cancer outside the pulmonary tract. I wrote my masters thesis on mortality trends in skeletal system sarcomas, including osteosarcoma, chondrosarcoma, and Ewing's sarcoma. I have also published, and/or presented at professional conferences, a number of studies that examined risk factors for developing cancers of the female reproductive system (and other organs). One of these, which was published in the American Journal of Health Education in 2003, has been designated as "Required Reading" at Johns Hopkins University.
I've also done some interesting work in geographic trend analysis of mortality due to cerebrovascular and cardiovascular diseases. About 10 years ago, when I was at the U of A, Dr. Michael Young (now Dean of Research at New Mexico State University) and I did some non-linear mortality trend analyses of age-adjusted death rates from stroke. At the time, official data suggested Arkansas had (only) the 11th highest stroke death rate amongst the 50 US states. However, our trend analyses suggested it was already #1, or would be very soon. Within just a couple of years, new data showed we were correct! Partly because we were so busy doing other things, but mostly because of the intensely negative political fallout that publication of such a study would no doubt have generated, we never did submit our work for publication. I wish now that we had, though!
Other Miscellaneous Interests
I have broad and diverse miscellaneous academic and professional interests, but have the most expertise in pathology, pharmacology, pharmaceutical chemistry, toxicology, cosmology, astrophysics, mathematics, statistics, nuclear weapons, military science, politics, forensic science, criminal law, and theology.
Building Big Draglines
I grew up in the coal mines with my Dad, and started working for him in the 7th grade - laboring, blasting, and operating heavy equipment (i.e. bulldozers, end loaders, and draglines). I became a fan of "walking draglines" and surface mining at a young age, and for many years (off-and-on) I helped build and work on draglines, mostly as a Project Manager for the White Equipment Corporation. You can see one of the machines I helped put together in two videos, located here [] and here []. It is a specially modified Rapier W2000. It was, at the time, the largest of its kind ever built.
The original machine was purchased and disassembled in Pottsville, Pennsylvania over several months, then transported to Bessemer, Pennsylvania in a total of 188 individual tractor-trailer loads. During the reassembly, we lengthened the boom from 285 to 315 feet and added a bigger bucket (45 cubic yards, instead of 30). This upsizing required extensive engineering modifications to the ballast, hoist and drag drums, house, and swing gear support structures to allow for much heavier stresses. This unique and awesome machine was then re-erected for the ESSROC Corporation between 1991 and 1993, with the Bucyrus-Erie/MINSERCO Corporation and British engineers and electricians assisting with parts of the erection and commissioning processes. The entire (huge) job ran for about 30 months, involved more than 30 employees, and was budgeted at over $2 million. Unfortunately, I recently found out that this beauty has been idle for at least 2 years now, and will probably be scrapped at the site.
My Education and Other Qualifications
I earned a Bachelor of Science degree in Chemistry from the Missouri University of Science and Technology (formerly the University of Missouri-Rolla). My emphasis areas included biochemistry, pharmaceutical chemistry, and the life sciences. During my undergraduate studies, I worked for a semester as an intern in the laboratory of Dr. Donald Siehr, researching the molecular genetics of the beta-lactamase operon in Saccharomyces cerevisiae.
After graduating with my B.S., I attended Southern Illinois University-Carbondale for one year, taking graduate courses in immunology, virology, molecular biology, and microbiology. From 1985-86, I worked as a virology researcher in the Southern Illinois Cancer Research Laboratory under the direction of Dr. Hassan Rouhandeh, studying the oncogenicity and pathology of Herpes and Poxviruses in epithelial cell tissue culture. I left SIU-C in 1986 to take a job as a forensic chemist with the Illinois Bureau of Forensic Sciences, specializing in the analysis of pharmaceuticals, illicit drugs, and general chemical unknowns. I also served on two statewide Forensic Chemistry Section Committees (the Quantitation Committee and the Quality Control Committee), and also conducted some research developing new methods for rapid semi-quantitative analyses of cocaine and heroin using gas chromatography-mass spectrometry with ion trap detection (GC-MS/ITD). In 1987, I sat for a non-credit graduate course in mammalian cloning at the University of Illinois-Springfield.
I later earned a Master of Science degree in Health Science from the University of Arkansas. My emphasis area was in cancer epidemiology, with particular foci in the clinical epidemiology of unusual variants of lung cancer and mortality trends due to skeletal system cancers (sarcoma using non-linear modeling techniques. My masters thesis was entitled "Skeletal Sarcoma Mortality Trends in Arkansas are Confounded by Misdiagnosis of Fatal Lung Cancer Cases in the Oldest Old". During my masters program, I was elected to Phi Kappa Phi, graduated #1 in my class, was voted the "Most Outstanding Masters Student" award, and was awarded a Northwest Arkansas Cancer Challenge Fellowship in lung cancer epidemiology. The latter honor allowed me to spend part of a summer studying lung cancer epidemiology at the The Johns Hopkins University School of Medicine and the Bloomberg School of Public Health.
While at the University of Arkansas, I was the Assistant Director of the Health Education Projects Office, under one of the most accomplished health science researchers in the world, Dr. Michael E. Young. As a team, we conducted considerable research into risk factors for gynecological cancers, stroke mortality trends in Arkansas and the "stroke belt", and drug use and pregnancy prevention among teenagers. I also helped Dr. Young revise and update his nationally recognized and honored drug prevention program, "Keep a Clear Mind".
After completing my masters degree, I won the first Walton Distinguished Doctoral Fellowship in Health Science that was ever granted at the U of A. After completing four years of this teaching and research fellowship, working with Dr. Michael E. Young, and doing an internship in the Human Performance Laboratory under Dr. Ro DiBrezzo, I returned home to Illinois to help take care of my aging parents, and to (slowly) complete my dissertation and (eventually) obtain my Ph.D. degree.
Academic and Professional Honors, Awards, and Grants
- Child of Veterans Academic Scholarship
- University of Illinois at Urbana-Champaign
- $40,000 scholarship over 4 years
- Declined because my father wanted me to attend the University of Missouri-Rolla
- Kappa Mu Epsilon Mathematics Honor Fraternity
- Elected to membership, University of Missouri-Rolla Chapter
- For being in top 10% of mathematics students in U.S.
- Walton Distinguished Doctoral Fellowship in Health Science
- University of Arkansas, College of Health Professions
- $120,000 cash grant (plus tuition) over 4 years
- For outstanding research and teaching potential in health science
- Specializations in lung cancer and skeletal sarcomas
- Northwest Arkansas Cancer Challenge Education Grant
- Johns Hopkins University School of Medicine
- Johns Hopkins University Bloomberg School of Public Health
- $4,000 cash grant over 3 months
- For advanced education in lung cancer epidemiology
- Teaching Assistant Training Award (won twice)
- University of Arkansas, Center for Excellence in Teaching
- $650 cash grant over 2 years
- For outstanding overall teaching and training effectiveness
- 21st Annual Graduate Institute of Epidemiology and Biostatistics
- Johns Hopkins University School of Medicine
- Bloomberg School of Public Health
- Department of Epidemiology and Biostatistics
- $2,500 cash grant over one month
- For advanced study in lung cancer prevention
- Outstanding Masters Student in Health Science Award
- University of Arkansas, College of Education and Health Professions
- Declined award after winning Walton Distinguished Fellowship
- Phi Kappa Phi Honor Fraternity
- Elected to membership, University of Arkansas Chapter
- For being in top 2% of graduate students in the U.S.
- Northwest Arkansas Cancer Challenge Research Grant
- With Dr. Michael E. Young, Ph.D. (Principal Investigator)
- $8,000 cash grant for a one year project "Setting the [Research] Agenda"
- For developing research proposals in lung cancer prevention
My Featured Personal Articles at Wikipedia
I created and wrote (nearly) all of the substantive information in the following three articles myself. The first two were submitted to (successful) peer review, and the third will be when it is completely finished. I think I can make a good argument that these articles are more comprehensive sources than any other that is currently available in the world literature.
Wikipedia Awards and Peer Recognition
One of the nicest feelings on this Earth occurs when you receive recognition from your peers. The contributors here at Wikipedia have been exceptionally kind to me, and a few have even awarded me with particular accolades, which I semi-humbly display here.
|On 2 July 2011, Did you know? was updated with a fact from the article Basaloid squamous cell lung carcinoma, which you created or substantially expanded. The fact was ... that basaloid squamous cell lung carcinoma was first described in 1992 and declared a lung cancer variant by the World Health Organization in 1999? You are welcome to check how many hits the article got while on the front page (here's how, quick check) and add it to DYKSTATS if it got over 5,000. If you know of another interesting fact from a recently created article, then please suggest it on the Did you know? talk page.|
|The Exceptional Newcomer Award|
|For having the courage and ability to create new articles like Combined small cell lung carcinoma 03:30, 27 March 2010 (UTC)|
|The Medicine Barnstar|
|To Uploadvirus, for contributions to medical articles. Axl ¤ [Talk] 08:36, 16 April 2011 (UTC)|
|The Modest Barnstar|
|This barnstar is awarded to Uploadvirus for copy editing articles totalling over 4,000 words during the GOCE March copy edit drive. Thanks for participating! Dianna (talk) 01:46, 2 April 2012 (UTC)|
|The Copyeditor's Barnstar|
|This barnstar is awarded to Cliff "Uploadvirus" Knickerbocker for copy editing articles totalling over 30,000 words during the May 2012 copy edit drive. Your work is much appreciated! -- Dianna (talk) 00:40, 3 June 2012 (UTC)|
|The 10k Copy Edit Barnstar|
|This barnstar is awarded to Uploadvirus for copy editing a big article of 10,000 words or more during the Guild of Copy Editors May backlog elimination drive. Thanks so much for your help with the wikiproject! -- Dianna (talk) 00:42, 3 June 2012 (UTC)|
|Leaderboard Award – Number of 5k articles edited – Equal 5th Place|
|This Leaderboard Award is awarded to Uploadvirus for copy editing 4 articles of 5000 words or more during the Guild of Copy Editors May 2012 GOCE drive. Congratulations on winning this prestigious award. Thank you for your efforts. --Stfg (talk) 11:24, 4 June 2012 (UTC)|
|The Anti-Vandalism Barnstar|
|For your work removing vandalism. Doc James (talk · contribs · email) 11:32, 12 June 2012 (UTC)|
|The Most Excellent Order of the Caretaker's Star|
|For exceptional copyediting efforts during the GOCE July copy edit drive, editing articles with a combined total of 101,619 words, Cliff "Uploadvirus" Knickerbocker is presented with this exclusive, brilliant, Most Excellent Order of the Caretaker's Star. Thank you so much for helping out with copy edits. -- Dianna (talk) 01:55, 11 August 2012 (UTC)|
|Leaderboard Award – Number of articles edited – 4th Place|
|This Guild of Copy Editors Silver Award is awarded to Uploadvirus for copy editing 44 articles during the Guild of Copy Editors July 2012 GOCE drive. Congratulations on winning this prestigious award. Thank you for your efforts. -- Dianna (talk) 01:55, 11 August 2012 (UTC)|
|Leaderboard Award – Word Count – 3rd Place|
|This Guild of Copy Editors Silver Award is awarded to Uploadvirus for copy editing articles totalling 86,247 words during the Guild of Copy Editors July 2012 GOCE drive. Congratulations on winning this prestigious award. Thank you for your efforts. -- Dianna (talk) 01:55, 11 August 2012 (UTC)|
|Leaderboard Award – Number of 5K articles edited – 2nd Place|
|This Guild of Copy Editors Silver Award is awarded to Uploadvirus for copy editing five articles of 5,000 words or more during the Guild of Copy Editors July 2012 GOCE drive. Congratulations on winning this prestigious award. Thank you for your efforts. -- Dianna (talk) 01:55, 11 August 2012 (UTC)|
|The Teamwork Barnstar|
|Cliff, thanks for stepping forward to help with the barnstar preparations yesterday. It's so easy to make mistakes in that task , and I really valued the second pair of eyes. Thank you! Simon. --Stfg (talk) 11:54, 11 August 2012 (UTC)|
Articles Created or am "Primary Author" On
- Acinar adenocarcinoma
- Acinic cell carcinoma of the lung
- Adenosquamous lung carcinoma
- Adjuvant radiotherapy
- Anaplastic carcinoma
- Basaloid large cell carcinoma of the lung
- Basaloid squamous cell lung carcinoma
- Bronchioloalveolar carcinoma
- Embryonal rhabdomyosarcoma
- EML4-ALK positive lung cancer
- Epithelial-myoepithelial carcinoma of the lung
- Fetal adenocarcinoma
- Giant cell carcinoma of the lung
- Inflammatory myeloblastic tumor
- Large cell lung carcinoma
- Large cell neuroendocrine carcinoma
- Mucinous cystadenocarcinoma of the lung
- Mucoepidermoid carcinoma
- Papillary adenocarcinoma
- Pulmonary cyst
- Rare lung cancers
- Rhabdoid lung carcinoma
- Salivary gland-like carcinoma of the lung
- Sarcomatoid carcinoma
- Sarcomatoid carcinoma of the lung
- Solitary fibrous tumor
- Targeted therapy of lung cancer
- Treatment of lung cancer
- Treatment of rare lung cancers
Articles Wherein I've Done Major Editing
- Adenocarcinoma of the lung
- Bone tumors
- Carbohydrate chemistry
- Carcinoma in situ
- Cognitive behavioral therapy
- Data mining
- Diastolic heart failure
- Diffuse panbronchiolitis
- Forensic chemistry
- Georgy Zhukov
- Hairy cell leukemia
- Hypertensive emergency
- Interferon alfa
- Ion track
- Medal of Honor
- Loop quantum gravity
- Merkel cell carcinoma
- Mucoepidermoid carcinoma
- Nuclear warfare
- Quantum mechanics
- Respiratory disease
- Sebaceous carcinoma
- Soft tissue therapy
- Squamous cell carcinoma
- Tay-Sachs disease
- Thoracic outlet syndrome
Articles Wherein I've Done Minor Editing
- Anthropometric cosmetology
- Artificial intuition
- Atypical depression
- Black hole
- Cervical cancer
- Chemotherapy regimens
- Chernobyl disaster effects
- Clear cell adenocarcinoma of the vagina
- Clear cell tumor
- Conjugated microporous polymer
- Cytoskeletal drugs
- Deep Vein Thrombosis
- Endocannabinoid system
- Genetic erosion
- Hydraulic fracturing
- Induced pluripotent stem cell
- Jacob sheep
- Kegel exercises
- Large cell carcinoma
- Loop quantum cosmology
- Lung cancer
- Lymphoepithelioma-like carcinoma
- Pancreatic cancer
- Platelet-derived growth factor
- Pleural fibroma
- Pulmonary sequestration
- Signet ring cell squamous cell carcinoma
- Small cell carcinoma
- Sodium Reactor Experiment
- Speed of light
- Subatomic scale
- Template:Epithelial neoplasms
- Template:Respiratory neoplasia
- Template:Respiratory system procedures
- Uniform motion
- United States War Crimes
- Vitamin B12 deficiency
- Warfarin necrosis
- 2010 Israel–Lebanon border clash
Tools and Other Useful Links
Plagiarism of my Writing
Some of the writing I've done here at Wikipedia has (apparently) been plagiarized verbatim in the peer-reviewed literature! Here are cites for a few examples I've run across:
Krishnamurthy A, Vijayalakshmi N, Majhi U. A fatal case of pure giant cell carcinoma of the lung. J Can Res Ther 2011;7:363-5. - the authors copied and used part of an introduction I first wrote for my award-winning article on combined small cell lung carcinoma, and that I also used in several other articles.
Krčedinac J, Panjković M, Božanić S, Samardžija G, Stojanović M. Large cell lung carcinoma with rhabdoid phenotype: Case report. Arch Oncol 2011;19:34-6. - in their conclusion, the authors copied from my large cell lung carcinoma with rhabdoid phenotype Wikipedia article.
Google searches of various phrases reveal many other examples. Please, folks - when you use someone else's work, just give them credit with a cite! That's all we researchers ask!
- "It is not the critic who counts, not the man who points out how the strong man stumbles, or where the doer of deeds could have done them better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who strives valiantly, who errs, who comes short again and again, because he knows there is no effort without error and shortcoming. But those who do actually strive to do the deeds, who know great enthusiasms, the great devotions, who spends himself in a worthy cause, who at the best knows in the end the triumph of high achievement, and who at the worst, if he fails, at least fails while daring greatly, so that his place shall never be with those cold and timid souls who neither know victory nor defeat" - Theodore Roosevelt
- "We make a living by what we get, we make a life by what we give" - Winston Churchill
- "I would be the most content if my children grew up to be the kind of people who think decorating consists mostly of building enough bookshelves" - Anna Quindlen
- "The Honorable General" is the first person to step foot on the battlefield, and the last to leave it - whether standing on his feet, or lying in his body bag. He is the first to dig a shovelful of Earth, and the last to take credit for the improvements wrought. He makes certain his troops are well fed, clad, and rested before takes a mouthful of sustenance, dons his field jacket, or places his head upon his pillow. During a struggle, The Honorable General dedicates himself to educating his troops as to their great might and even greater worth. He continuously assures them of the righteousness of their campaign, and of its inevitable success. He constantly provides all members of his command with the tools and the personal leadership they need to be victorious. If the battle turns against him, he is the first to claim the fault for himself, and the last to criticize the performance of his followers. When the battle is finally won, he is the first to offer praise to those who persevered under his flawed command, and the last to claim responsibility for the fruits of their victory. Most importantly, The Honorable General never forgets that his ultimate duty is to strive to funnel all available resources into the hearts and heads of his troops - for in only that way can he insure, beyond doubt, not just that his troops will conquer all, but that they will always strive to remain as honorable as he is." - Cliff Knickerbocker
In Memoriam 
My Mother: Esther Mae Knickerbocker (b. 14 April 1932, d. 24 March 2010)
My Father: Roger Cliff Knickerbocker (b. 19 June 1915, d. 6 February 1977)
My Stepfather: Frank L. White (b. 11 July 1922, d. 14 December 2010)
My Interim Father: Dr. Ronald Browning, Ph.D. (b. 24 April 1934, d. 27 April 1992)
My Research Father: Dr. Michael E. Young, Ph.D. (b. 26 March 1950, fl. 2013)
My Second Mother: Ora Ritsch (b. 21 May 1904, d. ?)
- Cliff L. Knickerbocker, M.S.
- Adnomery Medical Research Institute
- 518 Kentucky Street
- St. Joseph, MO 64505
- TEL: (618) 579-7880